Literature DB >> 36099119

Synchronous Anal Canal Cancer and Cervical Cancer: Report of a Case and Management Implication.

Carlo Guglielmo Cattaneo1, Daniela Musio1, Federica Tanzi2, Giacomo Guidi2, Innocenza Palaia2, Vincenzo Tombolini1, Francesca DE Felice3.   

Abstract

BACKGROUND: This is the case report of a synchronous anal canal cancer and cervical cancer in a patient who underwent definitive chemoradiotherapy (CRT) and radical surgery for anal canal and cervical carcinoma, respectively. CASE REPORT: A 55-year-old woman was diagnosed with cT4a cN1 Mx anal canal squamous cell carcinoma and stage IA2 cervical squamous cell carcinoma, based on biopsy and imaging. Definitive CRT consisted of radiotherapy (total dose of 59.4 Gy) and concomitant mitomycin (10 mg/m2) and 5-fluorouracil (750 mg/m2/5 daily continuous infusion) during the first and last week of radiation. The patient exhibited a complete clinical and radiological response. A radical hysterectomy with pelvic lymphadenectomy was then performed. At the last follow-up (30 months), the patient is still disease-free without any treatment-associated complications.
CONCLUSION: There is limited information in the literature regarding treatment strategy and outcome of patients with synchronous anal canal and cervical cancer. A two-step treatment, including CRT and radical hysterectomy, is likely to be accepted as valid option.
Copyright © 2022, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  Anal canal cancer; cervical cancer; chemoradiotherapy; multidisciplinary; radiotherapy; surgery; treatment

Mesh:

Substances:

Year:  2022        PMID: 36099119      PMCID: PMC9463915          DOI: 10.21873/invivo.12988

Source DB:  PubMed          Journal:  In Vivo        ISSN: 0258-851X            Impact factor:   2.406


  8 in total

1.  Cancer statistics, trends, and multiple primary cancer analyses from the Surveillance, Epidemiology, and End Results (SEER) Program.

Authors:  Matthew J Hayat; Nadia Howlader; Marsha E Reichman; Brenda K Edwards
Journal:  Oncologist       Date:  2007-01

2.  NCCN clinical practice guidelines in oncology. Anal carcinoma.

Authors:  Paul F Engstrom; Juan Pablo Arnoletti; Al B Benson; Jordan D Berlin; J Michael Berry; Yi-Jen Chen; Michael A Choti; Harry S Cooper; Raza A Dilawari; Dayna S Early; Peter C Enzinger; Marwan G Fakih; James Fleshman; Charles Fuchs; Jean L Grem; James A Knol; Lucille A Leong; Edward Lin; Mary F Mulcahy; Eric Rohren; David P Ryan; Leonard Saltz; David Shibata; John M Skibber; William Small; Constantinos Sofocleous; James Thomas; Alan P Venook; Christopher Willett
Journal:  J Natl Compr Canc Netw       Date:  2010-01       Impact factor: 11.908

3.  Definitive Chemoradiotherapy for Anal Carcinoma: Long-Term Results Based on Consistent Time-to-Event Endpoints.

Authors:  Francesca De Felice; Maria Teresa Martinetti; Simone Orelli; Nadia Bulzonetti; Daniela Musio; Vincenzo Tombolini
Journal:  Oncology       Date:  2017-09-16       Impact factor: 2.935

Review 4.  Vulvar and Anal Intraepithelial Neoplasia: Terminology, Diagnosis, and Ancillary Studies.

Authors:  Eric J Yang; Christina S Kong; Teri A Longacre
Journal:  Adv Anat Pathol       Date:  2017-05       Impact factor: 3.875

5.  Control and Risk Factors of Nausea and Vomiting in Patients With Cervical Cancer Receiving Radiotherapy.

Authors:  Akane Uno; Senri Yamamoto; Hirotoshi Iihara; Hironori Fujii; Chiyoko Makita; Yoh Hayasaki; Yukino Ueda; Masaya Ito; Motoki Takenaka; Tomoyasu Kumano; Minako Mori; Moeka Yasue; Hiroko Kato-Hayashi; Ryo Kobayashi; Ken-Ichirou Morishige; Masayuki Matsuo; Hideki Hayashi; Akio Suzuki
Journal:  Anticancer Res       Date:  2022-06       Impact factor: 2.480

6.  Radiotherapy of cervical cancer.

Authors:  C Chargari; K Peignaux; A Escande; S Renard; C Lafond; A Petit; D Lam Cham Kee; C Durdux; C Haie-Méder
Journal:  Cancer Radiother       Date:  2021-12-23       Impact factor: 1.018

7.  Intensity-modulated radiotherapy for synchronous cancer of the anal canal and cervix.

Authors:  Terufumi Kawamoto; Kei Ito; Takuya Shimizuguchi; Satoshi Kito; Keiji Nihei; Keisuke Sasai; Katsuyuki Karasawa
Journal:  Oncol Lett       Date:  2018-07-30       Impact factor: 2.967

8.  Survival Nomograms after Curative Neoadjuvant Chemotherapy and Radical Surgery for Stage IB2-IIIB Cervical Cancer.

Authors:  Claudia Marchetti; Francesca De Felice; Anna Di Pinto; Alessia Romito; Angela Musella; Innocenza Palaia; Marco Monti; Vincenzo Tombolin; Ludovico Muzii; PierLuigi Benedetti Panici
Journal:  Cancer Res Treat       Date:  2017-07-19       Impact factor: 4.679

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.